Abou Diane S, Pickett Juile, Mattson John E, Thorek Daniel L J
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Johns Hopkins University Applied Physics Laboratory, 11100 Johns Hopkins Road, Laurel, MD 20723-6099, USA.
Appl Radiat Isot. 2017 Jan;119:36-42. doi: 10.1016/j.apradiso.2016.10.015. Epub 2016 Nov 4.
The alpha particle emitter Radium-223 dichloride (RaCl) has recently been approved for treatment of late-stage bone metastatic prostate cancer. There is considerable interest in studying this new agent outside of the clinical setting, however the supply of Ra is limited and expensive. We have engineered a Ra microgenerator using traces of Ac previously generated from cyclotron-produced Ac. Radiochemically pure RaCl was made, characterized, evaluated in vivo, and the source was recovered in high yield for regeneration of the microgenerator.
α粒子发射体二氯化镭-223(RaCl)最近已被批准用于治疗晚期骨转移性前列腺癌。人们对在临床环境之外研究这种新制剂有相当大的兴趣,然而,镭的供应有限且昂贵。我们利用回旋加速器产生的锕先前产生的微量锕设计了一种镭微型发生器。制备了放射化学纯的二氯化镭,对其进行了表征、体内评估,并以高收率回收了源以再生微型发生器。